Newsroom

Recent Press Releases

December 09, 2024
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
December 09, 2024
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

Recent Company Statements

October 16, 2024
Kite Appoints Gallia Levy, MD, PhD, as Global Head of Clinical Development and Laura Alquist as Global Head of Technical Operations

Explore More

Media Inquiries

Gilead Newsroom